In conclusion, we conducted exhaustive gene expression analysis of STS patients and in vitro growth inhibition assays using an MFH cell line to test the hypothesis that the gene combination of MIF and SCD1 (identified by a bioinformatics approach) is not only a diagnostic marker for discrimination between MFH and MFS, but also a prognostic marker for the overall outcome of STS. This evidence concerns the gene MIF and telomere syndrome.